Kyowa Kirin Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Abdul Mullick
- Full Time Employees
- 5,161
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Otemachi Financial City Grand Cube Tokyo TY Japan 100-0004
- IPO Date
- Aug 22, 1949
- Website
- kyowa-kirin.co.jp
- Similar Companies
- Business
- Kyowa Kirin Co., Ltd. (4151.T) is a Japan-based global specialty pharmaceutical company that researches, develops, manufactures, and commercializes innovative prescription medicines focused on high unmet medical needs in the therapeutic areas of bone and mineral disorders; intractable hematological diseases and hemato-oncology; and rare diseases. Founded in 1949 and headquartered in Tokyo, Japan, the company leverages state-of-the-art antibody engineering technologies and hematopoietic stem cell gene therapy to drive its technology-driven drug discovery pipeline, which includes candidates such as AMG531 for aplastic anemia, KHK4083/AMG 451 for atopic dermatitis and asthma, and KK2845 for acute myeloid leukemia. Its main products encompass biologics and ethical drugs targeting renal anemia, leukemia, cancer, allergies, hypertension, chronic kidney disease, immunological disorders, nephrology, oncology, and central nervous system conditions; the company also produces medical and industrial raw materials including amino acids and nucleic acid-related compounds, and operates biosimilar pharmaceuticals through subsidiaries. Kyowa Kirin maintains a global footprint with operations across Japan and Asia Pacific via subsidiaries like Kyowa Kirin Korea and Kyowa Kirin Taiwan; Europe, Middle East, and Africa through Kyowa Kirin International plc in the UK and affiliates in France, Germany, Spain, Italy, and the Nordic countries; and North America via Kyowa Kirin USA Holdings, Inc., including a new manufacturing facility under construction in Sanford, North Carolina, set to open in 2027. Recent major developments include the January 2024 acquisition of Orchard Therapeutics for $477.6 million to bolster gene therapy capabilities; a November 2024 global collaboration with Kura Oncology on ziftomenib, an oral menin inhibitor for acute myeloid leukemia and other hematologic malignancies, featuring a $330 million upfront payment to Kura, up to $1.161 billion in milestones, and shared US commercialization; and the ongoing construction of the HB7 building at its Takasaki Plant to accelerate biopharmaceutical development.
Company News
Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
Kyowa Kirin stops development of skin condition treatment
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin (OTCMKTS:KYKOF) Trading Down 4.5% – Time to Sell?
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company